Exchange: NASDAQ·Updated 10:26 AM EDT
CTMX logo

CTMX CytomX Therapeutics Inc

$2.36
$0.13
(5.83%)
Today
EarningsNov 5
Mkt Cap$485.92M
Vol404,536.00

About CTMX

CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies to address unmet need in oncology. The firm focuses on the field of antibody masking technologies through the development of its Probody therapeutic platform. The company was founded by Frederick W. Gluck, Nancy E. Stagliano, and Patrick S. Daugherty in February 2008 and is headquartered in South San Francisco, CA.
35

Bearish Sentiment

How do you feel about CTMX?

Bionco
$CTMX Don’t be frustrated if we still don’t have mature mOS and mPFS data by mid-November. This is truly great news!
7
Bionco
$CTMX I expect an announcement on November 4 that the Q3 ER is scheduled for November 16. Based on my medical knowledge, the mOS data from the dose escalation and expansion cohorts should be available by then. Hopefully, we’ll also get the mPFS data from the optimization cohorts. I just hope the damned management finally gives us some meaningful trial updates. The stock price has been steadily declining ever since the last update. It's so frustrating. I continue to believe CX2051 alone will deliver a mOS of ~14 months, roughly double that of currently available treatments for 3 line+ patients.
4
Bionco
$CTMX Let's see if we can get the mOS data from the dose-escalation and expansion cohorts, along with the mPFS data from the optimization cohorts, in the November Q3 ER. If the ER is scheduled for mid-November, there's a good chance these data will be available. Otherwise, the delay could be a very strong indication that patients are experiencing longer-than-expected survival and deeper, more durable responses, leaving the mOS data or (and) mPFS from optimization exhorts still immature!
6
HoldenMeown
$CTMX They’re not even close to done. There will be positive movement with the Varseta-M (CX-2051) Phase 1 data before year’s end.
1
HoldenMeown
$CTMX Then I suggest you cut your losses and get out. The rest of us are waiting for Varseta-M (CX-2051) Phase 1 monotherapy data.
1
HoldenMeown
$CTMX We’re not going to get any significant gains until they give us an update on Varseta-m sometime before year’s end. If it actually goes down, it will be a huge buying opportunity.
1
metalcook
$CTMX open label trial.. highest short % ever... 20%. Whats happening. Only 8 trial sites involved.
Gator5326
$CTMX It sucks but no worse then any other stock in this market. Good numbers will remove our pain. I believe and hold. 😎
Goyimlivesmatter
$CTMX bounced off support 2.70.. thats good atleast 🤷🏻‍♂️. Double bottom perhaps.. need to hold 2.70 🦾
Disvan
$CTMX widespread selloff across market, especially riskier sectors, in anticipation of FED rate decision tomorrow. But this one seems overdone!
TonyPhils
$CTMX dont panic. they try to steal your share with cheap price. it almost october please patient

Advertisement|Remove ads.